Skip to main content
SpringerLink
Log in

Lessons for Precision Medicine from Lung Cancer

  • Chapter
  • First Online:
Precision in Pulmonary, Critical Care, and Sleep Medicine

Part of the book series: Respiratory Medicine ((RM))

  • 764 Accesses

Abstract

Precision medicine targets prevention and treatments based on phenotypic, biochemical, genetic, and psychosocial characteristics that determine individual variability. Personalized treatment has been a long-standing paradigm for lung cancer. Advances in our understanding of lung cancer biology over the past two decades have dramatically changed our approaches to evaluation and management. This chapter highlights three “lessons” that inform an increasingly precise approach to lung cancer and are applicable to other diseases. The lessons discuss how advances in disease understanding facilitate individualized treatment tools, use of these tools in personalized assessments, and the importance of a holistic approach to the individual patient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. World Health Organization. Cancer 2018. Available from: http://www.who.int/en/news-room/fact-sheets/detail/cancer. Accessed 27 Aug 2018.

  3. World Health Organization. The top 10 causes of death 2018. Available from: http://www.who.int/mediacentre/factsheets/fs310/en/index1.html. Accessed 27 Aug 2018.

  4. Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Schroeder SA. Shattuck Lecture. We can do better–improving the health of the American people. N Engl J Med. 2007;357(12):1221–8.

    Article  CAS  PubMed  Google Scholar 

  6. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER cancer statistics review, 1957–2015. Bethesda: National Cancer Institute; 2015.

    Google Scholar 

  7. Centers for Disease Control and Prevention. History of the surgeon general’s reports on smoking health 2018. Available from: https://www.cdc.gov/tobacco/data_statistics/sgr/history/index.htm. Accessed 28 Aug 2018.

  8. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol. 2007;25(5):561–70.

    Article  PubMed  Google Scholar 

  9. Reck M, Rabe KF. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med. 2017;377(9):849–61.

    Article  CAS  PubMed  Google Scholar 

  10. Jemal A, Miller KD, Ma J, Siegel RL, Fedewa SA, Islami F, et al. Higher lung cancer incidence in young women than young men in the United States. N Engl J Med. 2018;378(21):1999–2009.

    Article  PubMed  PubMed Central  Google Scholar 

  11. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: lung and bronchus cancer. Available from: https://seer.cancer.gov/statfacts/html/lungb.html. Accessed 28 Aug 2018.

  12. Detterbeck FC. Achieving clarity about lung cancer and opacities. Chest. 2017;151(2):252–4.

    Article  PubMed  Google Scholar 

  13. Centers for Disease Control and Prevention. What are the risk factors for lung cancer 2018. Available from: https://www.cdc.gov/cancer/lung/basic_info/risk_factors.htm. Accessed 28 Aug 2018.

  14. MacMahon H, Naidich DP, Goo JM, Lee KS, Leung ANC, Mayo JR, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology. 2017;284(1):228–43.

    Article  PubMed  Google Scholar 

  15. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605–44.

    Article  Google Scholar 

  16. Moore SC, Lee IM, Weiderpass E, Campbell PT, Sampson JN, Kitahara CM, et al. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Intern Med. 2016;176(6):816–25.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst. 2003;95(6):470–8.

    Article  PubMed  Google Scholar 

  18. Omenn GS, Goodman G, Thornquist M, Grizzle J, Rosenstock L, Barnhart S, et al. The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers. Cancer Res. 1994;54(7 Suppl):2038s–43s.

    CAS  PubMed  Google Scholar 

  19. Tammemagi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368(8):728–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Tammemagi CM, Pinsky PF, Caporaso NE, Kvale PA, Hocking WG, Church TR, et al. Lung cancer risk prediction: prostate, lung, colorectal and ovarian cancer screening trial models and validation. J Natl Cancer Inst. 2011;103(13):1058–68.

    Article  PubMed  PubMed Central  Google Scholar 

  21. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.

    Article  Google Scholar 

  22. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–67.

    Article  CAS  PubMed  Google Scholar 

  23. Ou SH. Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy? J Clin Pathol. 2013;66(10):839–46.

    Article  PubMed  Google Scholar 

  24. Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29(15):2046–51.

    Article  PubMed  PubMed Central  Google Scholar 

  28. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer, Version 3.2019 – January 18, 2019: National Comprehensive Cancer Network; 2019 [11 February 2019]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Referenced with permission from the NCCN Guidelines® for Non-Small Cell Lung Cancer V.6.2018 © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed 17 Aug 2018. Available online at www.NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

  29. Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, et al. Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer. 2015;121(4):631–9.

    Article  CAS  PubMed  Google Scholar 

  30. Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, Tanoue LT, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e211S–e50S.

    Article  PubMed  Google Scholar 

  31. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.

    Article  PubMed  Google Scholar 

  32. Farjah F, Flum DR, Ramsey SD, Heagerty PJ, Symons RG, Wood DE. Multi-modality mediastinal staging for lung cancer among medicare beneficiaries. J Thorac Oncol. 2009;4(3):355–63.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Vokes EE, Govindan R, Iscoe N, Hossain AM, San Antonio B, Chouaki N, et al. The impact of staging by positron-emission tomography on overall survival and progression-free survival in patients with locally advanced NSCLC. J Thorac Oncol. 2018;13(8):1183–8.

    Article  PubMed  Google Scholar 

  34. Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med. 2009;361(1):32–9.

    Article  CAS  PubMed  Google Scholar 

  35. Viney RC, Boyer MJ, King MT, Kenny PM, Pollicino CA, McLean JM, et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol. 2004;22(12):2357–62.

    Article  PubMed  Google Scholar 

  36. van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359(9315):1388–93.

    Article  PubMed  Google Scholar 

  37. Annema JT, van Meerbeeck JP, Rintoul RC, Dooms C, Deschepper E, Dekkers OM, et al. Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. JAMA. 2010;304(20):2245–52.

    Article  CAS  PubMed  Google Scholar 

  38. Boffa DJ, Allen MS, Grab JD, Gaissert HA, Harpole DH, Wright CD. Data from The Society of Thoracic Surgeons General Thoracic Surgery database: the surgical management of primary lung tumors. J Thorac Cardiovasc Surg. 2008;135(2):247–54.

    Article  PubMed  Google Scholar 

  39. Seder CW, Wright CD, Chang AC, Han JM, McDonald D, Kozower BD. The society of thoracic surgeons general thoracic surgery database update on outcomes and quality. Ann Thorac Surg. 2016;101(5):1646–54.

    Article  PubMed  Google Scholar 

  40. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1986;4(5):702–9.

    Article  CAS  PubMed  Google Scholar 

  41. Bolliger CT, Wyser C, Roser H, Soler M, Perruchoud AP. Lung scanning and exercise testing for the prediction of postoperative performance in lung resection candidates at increased risk for complications. Chest. 1995;108(2):341–8.

    Article  CAS  PubMed  Google Scholar 

  42. Alam N, Park BJ, Wilton A, Seshan VE, Bains MS, Downey RJ, et al. Incidence and risk factors for lung injury after lung cancer resection. Ann Thorac Surg. 2007;84(4):1085–91; discussion 91.

    Article  PubMed  Google Scholar 

  43. Ferguson MK, Dignam JJ, Siddique J, Vigneswaran WT, Celauro AD. Diffusing capacity predicts long-term survival after lung resection for cancer. Eur J Cardiothorac Surg. 2012;41(5):e81–6.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Brunelli A, Kim AW, Berger KI, Addrizzo-Harris DJ. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e166S–e90S.

    Article  CAS  PubMed  Google Scholar 

  45. de Koning HJ, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160(5):311–20.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Moyer VA, Force USPST. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5):330-8.

    Article  PubMed  Google Scholar 

  47. Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med. 2013;369(3):245–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Caverly TJ, Fagerlin A, Wiener RS, Slatore CG, Tanner NT, Yun S, et al. Comparison of observed harms and expected mortality benefit for persons in the veterans health affairs lung cancer screening demonstration project. JAMA Intern Med. 2018;178(3):426–8.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Katki HA, Kovalchik SA, Berg CD, Cheung LC, Chaturvedi AK. Development and validation of risk models to select ever-smokers for CT lung Cancer screening. JAMA. 2016;315(21):2300–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Tammemagi MC. Selecting lung cancer screenees using risk prediction models-where do we go from here. Transl Lung Cancer Res. 2018;7(3):243–53.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Mazzone PJ, Silvestri GA, Patel S, Kanne JP, Kinsinger LS, Wiener RS, et al. Screening for lung cancer: CHEST guideline and expert panel report. Chest. 2018;153(4):954–85.

    Article  PubMed  Google Scholar 

  52. Mountain CF, Carr DT, Anderson WA. A system for the clinical staging of lung cancer. Am J Roentgenol Radium Ther Nucl Med. 1974;120(1):130–8.

    Article  CAS  PubMed  Google Scholar 

  53. Detterbeck FC, Lewis SZ, Diekemper R, Addrizzo-Harris D, Alberts WM. Executive summary: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):7S–37S.

    Article  CAS  PubMed  Google Scholar 

  54. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e142S–e65S.

    Article  PubMed  Google Scholar 

  55. Ost DE, Jim Yeung SC, Tanoue LT, Gould MK. Clinical and organizational factors in the initial evaluation of patients with lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e121S–e41S.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Wang Memoli JS, Nietert PJ, Silvestri GA. Meta-analysis of guided bronchoscopy for the evaluation of the pulmonary nodule. Chest. 2012;142(2):385–93.

    Article  PubMed  Google Scholar 

  57. Ost DE, Ernst A, Lei X, Kovitz KL, Benzaquen S, Diaz-Mendoza J, et al. Diagnostic yield and complications of bronchoscopy for peripheral lung lesions. Results of the AQuIRE Registry. Am J Respir Crit Care Med. 2016;193(1):68–77.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Hofman P. Liquid biopsy for early detection of lung cancer. Curr Opin Oncol. 2017;29(1):73–8.

    Article  CAS  PubMed  Google Scholar 

  59. Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, et al. Liquid biopsy for advanced non-small cell lung Cancer (NSCLC): a statement paper from the IASLC. J Thorac Oncol. 2018;13:1248.

    Article  PubMed  Google Scholar 

  60. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–60.

    Article  PubMed  Google Scholar 

  61. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist. 2009;14(3):253–63.

    Article  CAS  PubMed  Google Scholar 

  62. Al-Saleh K, Quinton C, Ellis PM. Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis. Curr Oncol. 2012;19(1):e9–e15.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Lauro S, Onesti CE, Righini R, Marchetti P. The use of bevacizumab in non-small cell lung cancer: an update. Anticancer Res. 2014;34(4):1537–45.

    CAS  PubMed  Google Scholar 

  64. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500.

    Article  CAS  PubMed  Google Scholar 

  65. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.

    Article  CAS  PubMed  Google Scholar 

  66. Perez-Moreno P, Brambilla E, Thomas R, Soria JC. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res. 2012;18(9):2443–51.

    Article  CAS  PubMed  Google Scholar 

  67. Paik PK, Varghese AM, Sima CS, Moreira AL, Ladanyi M, Kris MG, et al. Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component. Mol Cancer Ther. 2012;11(11):2535–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Carbone DP, Gandara DR, Antonia SJ, Zielinski C, Paz-Ares L. Non-small-cell lung cancer: role of the immune system and potential for immunotherapy. J Thorac Oncol. 2015;10(7):974–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.

    Article  CAS  PubMed  Google Scholar 

  70. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–29.

    Article  CAS  PubMed  Google Scholar 

  71. Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–92.

    Article  CAS  PubMed  Google Scholar 

  72. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–51.

    Article  CAS  PubMed  Google Scholar 

  73. Beattie J, Yarmus L, Wahidi M, Rivera MP, Gilbert C, Maldonado F, et al. The immune landscape of non-small-cell lung cancer. Utility of cytologic and histologic samples obtained through minimally invasive pulmonary procedures. Am J Respir Crit Care Med. 2018;198(1):24–38.

    Article  CAS  PubMed  Google Scholar 

  74. Owada-Ozaki Y, Muto S, Takagi H, Inoue T, Watanabe Y, Fukuhara M, et al. Prognostic impact of tumor mutation burden in patients with completely resected non-small cell lung cancer: brief report. J Thorac Oncol. 2018;13(8):1217–21.

    Article  PubMed  Google Scholar 

  75. Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378(21):1976–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Presley CJ, Tang DW, Soulos PR, Chiang AC, Longtine JA, Adelson KB, et al. Association of broad-based genomic sequencing with survival among patients with advanced non-small cell lung cancer in the community oncology setting. JAMA. 2018;320(5):469–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Wennberg JE, Fisher ES, Skinner JS. Geography and the debate over Medicare reform. Health Aff (Millwood). 2002;Suppl Web Exclusives:W96–114.

    Article  Google Scholar 

  79. Langer CJ. Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer? J Clin Oncol. 2013;31(27):3303–6.

    Article  CAS  PubMed  Google Scholar 

  80. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733–42.

    Article  CAS  PubMed  Google Scholar 

  81. Ferrell BR, Temel JS, Temin S, Alesi ER, Balboni TA, Basch EM, et al. Integration of palliative care into standard oncology care: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35(1):96–112.

    Article  PubMed  Google Scholar 

  82. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–8.

    Article  CAS  PubMed  Google Scholar 

  83. Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK, Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based C. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol. 2010;5(2):260–74.

    Article  PubMed  Google Scholar 

  84. Dubey S, Brown RL, Esmond SL, Bowers BJ, Healy JM, Schiller JH. Patient preferences in choosing chemotherapy regimens for advanced non-small cell lung cancer. J Support Oncol. 2005;3(2):149–54.

    PubMed  Google Scholar 

  85. Barry MJ, Edgman-Levitan S. Shared decision making–pinnacle of patient-centered care. N Engl J Med. 2012;366(9):780–1.

    Article  CAS  PubMed  Google Scholar 

  86. Geerse OP, Stegmann ME, Kerstjens HAM, Hiltermann TJN, Bakitas M, Zimmermann C, et al. Effects of shared decision making on distress and health care utilization among patients with lung cancer: a systematic review. J Pain Symptom Manag. 2018;56:975.

    Article  Google Scholar 

  87. Stacey D, Legare F, Lewis K, Barry MJ, Bennett CL, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017;4:CD001431.

    PubMed  Google Scholar 

  88. Centers for Medicare and Medicaid Services. Decision memo for screening for lung cancer with low dose computed tomography (LDCT) (CAG-00439N). Available from: https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=274.

  89. Tanner NT, Kanodra NM, Gebregziabher M, Payne E, Halbert CH, Warren GW, et al. The association between smoking abstinence and mortality in the National Lung Screening Trial. Am J Respir Crit Care Med. 2016;193(5):534–41.

    Article  CAS  PubMed  Google Scholar 

  90. Patz EF Jr, Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemagi MC, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014;174(2):269–74.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Mazzone PJ, Tenenbaum A, Seeley M, Petersen H, Lyon C, Han X, et al. Impact of a lung cancer screening counseling and shared decision-making visit. Chest. 2017;151(3):572–8.

    Article  PubMed  Google Scholar 

  92. Dai C, Shen J, Ren Y, Zhong S, Zheng H, He J, et al. Choice of surgical procedure for patients with non-small-cell lung cancer </= 1 cm or > 1–2 cm among lobectomy, segmentectomy, and wedge resection: a population-based study. J Clin Oncol. 2016;34(26):3175–82.

    Article  PubMed  Google Scholar 

  93. Ginsberg RJ, Rubinstein L. The comparison of limited resection to lobectomy for T1N0 non-small cell lung cancer. LCSG 821. Chest. 1994;106(6 Suppl):318S–9S.

    CAS  PubMed  Google Scholar 

  94. Bryant AK, Mundt RC, Sandhu AP, Urbanic JJ, Sharabi AB, Gupta S, et al. Stereotactic body radiation therapy versus surgery for early lung cancer among US veterans. Ann Thorac Surg. 2018;105(2):425–31.

    Article  PubMed  Google Scholar 

  95. Cao C, Wang D, Chung C, Tian D, Rimner A, Huang J, et al. A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019;157(1):362–73.e8.

    Article  PubMed  Google Scholar 

  96. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Grills IS, Mangona VS, Welsh R, Chmielewski G, McInerney E, Martin S, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol. 2010;28(6):928–35.

    Article  PubMed  Google Scholar 

  98. Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151(1):193–203.

    Article  PubMed  Google Scholar 

  99. Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA

    Brett C. Bade, Finbar T. Foley & Lynn T. Tanoue

Authors
  1. Brett C. Bade
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Finbar T. Foley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lynn T. Tanoue
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brett C. Bade .

Editor information

Editors and Affiliations

  1. Assistant Professor Pulmonary, Critical Care and Sleep Medicine Section, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA

    Jose L. Gomez

  2. Assistant Professor of Informatics, Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, USA

    Blanca E. Himes

  3. Boehringer-Ingelheim Endowed, Professor of Internal Medicine, Chief of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, USA

    Naftali Kaminski

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bade, B.C., Foley, F.T., Tanoue, L.T. (2020). Lessons for Precision Medicine from Lung Cancer. In: Gomez, J., Himes, B., Kaminski, N. (eds) Precision in Pulmonary, Critical Care, and Sleep Medicine. Respiratory Medicine. Humana, Cham. https://doi.org/10.1007/978-3-030-31507-8_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-31507-8_14

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-31506-1

  • Online ISBN: 978-3-030-31507-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation